←
Laura Graham17 posts
Laura Graham avatar

Laura Graham

@LauraGrahamMD

GU medical oncologist & clinical trialist at CU Anschutz | Director, Clinical GU Research Program | Prostate cancer research | Endurance athlete

◷ Joined June 2026▧ 3 Photos and videos
Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 16

Thanks to @UroToday for the opportunity to discuss our #SITC2026 findings! Combining T-cell engagement with targeted costimulation represents an exciting strategy in #mCRPC. Encouraging early clinical activity, with much more to learn.

Dual Antigen-Targeted T-Cell Engager Combination in Metastatic Castration-Resistant #ProstateCancer. @LauraGrahamMD @CUAnschutz joins @neerajaiims @DanaFarber to discuss #SITC26 data on pasritamig + JNJ-9401, a dual antigen-targeted T-cell engager combination in heavily pretreated #mCRPC: 73% PSA50, 47% PSA90. #WatchNow > bit.ly/48szlVg

Post attachment
Tanya Dorff avatar
⟳ Laura Graham retweeted
Tanya Dorff@TDorffOnc·Oct 28

Happening now - ASCO elections! @montypal has worked tirelessly through ASCO committees and now as president of MOASC to accelerate progress in cancer research and treatment. View all candidates and bios and vote now! Asco.org/elections

Post attachment
Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 8

Thanks, Mark! Enjoyed presenting these first clinical data exploring tumor-targeted CD28 costimulation alongside CD3 directed T cell engagement. Grateful for the collaborative effort from the J&J team, investigators, and especially the patients who made this research possible!

At #ESMO26 we introduced a new word, #RIPTAC, JNJ-6143. Introducing another innovation presented @sitcancer yesterday! FIH Investigational combo of Pasritamig our @JNJInnovMed KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 & signal 2 together! #MyCompany

Post attachmentPost attachment
Moffitt Cancer Center avatar
⟳ Laura Graham retweeted
Moffitt Cancer Center@MoffittNews·Nov 7

Dual-antigen T-cell engagement demonstrates encouraging clinical activity in advanced prostate cancer. At #SITC26, Laura Graham, MD of @CUDeptMedicine presents phase 1 results showing substantial PSA reductions and a manageable safety profile with combined KLK2 and PSMA targeting. #MoffittSITC26

Post attachmentPost attachmentPost attachment
Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 8

Thank you @sitcancer for the opportunity to share our work at #SITC26! It was a privilege to present these exciting early data and be part of such a fantastic meeting. Grateful to all the patients and collaborators who made this research possible! @drmnstein @CUCancerCenter

Thanks @LauraGrahamMD for a great presentation at #SITC26. Groundbreaking research is always the case at a @sitcancer Annual Meeting!

Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 8

Grateful to @drmnstein for his mentorship, collaboration, and leadership throughout this study. A privilege to work with such an outstanding team and help bring these exciting data to SITC!

Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 8

Great to speak with @OncLive about our #SITC2026 data combining KLK2×CD3 T-cell engagement with PSMA×CD28 costimulation in #mCRPC. Encouraging early results with deep, durable PSA responses and favorable safety profile. Excited about the potential of this approach!

WATCH: @LauraGrahamMD of @CUAnschutz discusses safety and efficacy data for JNJ-87189401 plus pasritamig in mCRPC @sitcancer #SITC26 #pcsm #oncology onclive.com/view/dr-graham-o…

Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 8

Encouraging safety at the recommended regimen: no grade ≥3 treatment-related AEs; 20% CRS, all grade 1. Grateful to the patients, investigators, and study team who made this work possible! Excited to see this approach move forward in phase 3. #SITC2026

Post attachment
Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 8

Excited to share our first-in-human #SITC2026 data combining pasritamig (KLK2×CD3) with JNJ-9401 (PSMA×CD28) in #mCRPC! At the recommended regimen (n=15): 73% PSA50 47% PSA90 27% undetectable PSA Promising early evidence for dual-antigen targeting with CD28 costimulation

Post attachmentPost attachment
Laura Graham avatar
Laura Graham@LauraGrahamMD·Nov 7

Great chatting with @OncLive about our upcoming #SITC26 presentation! Excited to share our first-in-human phase 1 results combining PSMA×CD28 costimulation with KLK2×CD3 T-cell engagement in #mCRPC. Looking forward to tomorrow's presentation!

Thank you to @LauraGrahamMD of @CUCancerCenter for stopping by to discuss her @sitcancer presentation on phase 1 data for the PSMAxCD28 T-cell engager JNJ-87189401 plus pasritamig in mCRPC. Stay tuned for her presentation on Saturday at #SITC26!

Post attachment
Laura Graham avatar
Laura Graham@LauraGrahamMD·Oct 31

Grateful to receive the 2026 Quintin Family Foundation–PCF Young Investigator Award, supporting our T-REX research in advanced prostate cancer. Thank you to PCF the Quintin Family Foundation, and my mentors Thomas Flaig, Lawrence Fong, and Mark Stein! @PCFnews #ProstateCancer

Post attachmentPost attachment